http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Jongyoon Shinn (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Smart pH-responsive nanomedicines for disease therapy
Shinn Jongyoon,Kwon Nuri,Lee Seon Ah,Lee Yonghyun 한국약제학회 2022 Journal of Pharmaceutical Investigation Vol.52 No.4
Background Currently nanomedicines are the focus of attention from researchers and clinicians because of the successes of lipid-nanoparticles-based COVID-19 vaccines. Nanoparticles improve existing treatments by providing a number of advantages including protection of cargo molecules from external stresses, delivery of drugs to target tissues, and sustained drug release. To prevent premature release-related side effects, stable drug loading in nanoformulations is required, but the increased stability of the formulation could also lead to a poor drug-release profile at the target sites. Thus, researchers have exploited differences in a range of properties (e.g., enzyme levels, pH, levels of reduced glutathione, and reactive oxygen species) between non-target and target sites for site-specific release of drugs. Among these environmental stimuli, pH gradients have been widely used to design novel, responsive nanoparticles. Area covered In this review, we assess drug delivery based on pH-responsive nanoparticles at the levels of tissues (tumor microenvironment, pH ~ 6.5) and of intracellular compartments (endosome and lysosome, pH 4.5–6.5). Upon exposure to these pH stimuli, pH-responsive nanoparticles respond with physicochemical changes to their material structure and surface characteristics. These changes include swelling, dissociation, or surface charge switching, in a manner that favors drug release at the target site (the tumor microenvironment region and the cytosol followed by endosomal escape) rather than the surrounding tissues. Expert opinion Lastly, we consider the challenges involved in the development of pH-responsive nanomedicines.
-
Recent progress in development and applications of second near? infrared (NIR-II) nanoprobes
Jongyoon Shinn,Sunyoung Lee,Hyon Kyong Lee,Jaeeun Ahn,Seon Ah Lee,Seonju Lee,이용현 대한약학회 2021 Archives of Pharmacal Research Vol.44 No.2
Optical probes for near-infrared (NIR) lighthave clear advantages over UV/VIS-based optical probes,such as their low levels of interfering auto-fl uorescenceand high tissue penetration. The second NIR (NIR-II) window(1000−1350 nm) off ers better light penetration, lowerbackground signal, higher safety limit, and higher maximumpermitted exposure than the fi rst NIR (NIR-I) window(650−950 nm). Therefore, NIR-II laser–based photoacoustic(PA) and fl uorescence (FL) imaging can off er higher sensitivityand penetration depth than was previously available,and deeper lesions can be treated in vivo by photothermaltherapy (PTT) and photodynamic therapy (PDT) with anNIR-II laser than with an NIR-I laser. Advances in creationof novel nanomaterials have increased options for improvinglight-induced bioimaging and treatment. Nanotechnologycan provide advantages such as good disease targetingability and relatively long circulation times to supplementthe advantages of optical technologies. In this review, wepresent recent progress in development and applications ofNIR-II light–based nanoplatforms for FL, PA, image-guidedsurgery, PDT, and PTT. We also discuss recent advances insmart NIR-II nanoprobes that can respond to stimuli in thetumor microenvironment and infl amed sites. Finally, we considerthe challenges involved in using NIR-II nanomedicinefor eff ective diagnosis and treatment.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
